DE60043759D1 - Therapeutically useful synthetic oligonucleotides - Google Patents

Therapeutically useful synthetic oligonucleotides

Info

Publication number
DE60043759D1
DE60043759D1 DE2000643759 DE60043759A DE60043759D1 DE 60043759 D1 DE60043759 D1 DE 60043759D1 DE 2000643759 DE2000643759 DE 2000643759 DE 60043759 A DE60043759 A DE 60043759A DE 60043759 D1 DE60043759 D1 DE 60043759D1
Authority
DE
Germany
Prior art keywords
therapeutically useful
synthetic oligonucleotides
useful synthetic
oligonucleotides
therapeutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2000643759
Other languages
German (de)
Inventor
Nigel C Phillips
Mario C Filion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics Inc
Original Assignee
Telesta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17032599P priority Critical
Priority to US22892500P priority
Application filed by Telesta Therapeutics Inc filed Critical Telesta Therapeutics Inc
Application granted granted Critical
Publication of DE60043759D1 publication Critical patent/DE60043759D1/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/18Type of nucleic acid acting by a non-sequence specific mechanism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide
DE2000643759 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides Active DE60043759D1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17032599P true 1999-12-13 1999-12-13
US22892500P true 2000-08-29 2000-08-29

Publications (1)

Publication Number Publication Date
DE60043759D1 true DE60043759D1 (en) 2010-03-11

Family

ID=26865979

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2000643759 Active DE60043759D1 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides
DE2000636019 Active DE60036019T2 (en) 1999-12-13 2000-12-12 Synthetic oligonucleotides which are therapeutically useful

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE2000636019 Active DE60036019T2 (en) 1999-12-13 2000-12-12 Synthetic oligonucleotides which are therapeutically useful

Country Status (17)

Country Link
US (2) US7157436B2 (en)
EP (2) EP1867718B1 (en)
JP (1) JP4772245B2 (en)
CN (2) CN101491536B (en)
AT (2) AT455851T (en)
AU (1) AU785212B2 (en)
CA (1) CA2393808A1 (en)
CZ (1) CZ20022372A3 (en)
DE (2) DE60043759D1 (en)
DK (2) DK1867718T3 (en)
ES (2) ES2288883T3 (en)
HU (1) HU0300627A3 (en)
IL (2) IL150196D0 (en)
MX (1) MXPA02005842A (en)
NO (1) NO330508B1 (en)
PT (1) PT1238070E (en)
WO (1) WO2001044465A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7314926B1 (en) 1999-04-08 2008-01-01 Antisoma Research Limited Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU6886301A (en) 2000-08-29 2002-03-13 Bioniche Life Sciences Inc Modulation of fas and fasl expression
DE60043759D1 (en) * 1999-12-13 2010-03-11 Bioniche Life Sciences Inc Therapeutically useful synthetic oligonucleotides
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
CA2457783A1 (en) * 2001-08-17 2003-02-27 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use to induce apoptosis
DK1432450T3 (en) * 2001-10-03 2006-05-15 Bioniche Life Sciences Inc Therapeutically useful triethyleneglycol cholesteryl-oliconucleotider
CN101160399A (en) * 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 Oligonucleotide compositions and their use for the modulation of immune responses
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
KR20060012622A (en) * 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 Synergistic treatment of cancer using immunomers in conjuction with chemotherapeutic agents
EP1851314A2 (en) * 2005-02-24 2007-11-07 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1863538A4 (en) * 2005-03-09 2009-01-14 Baylor College Medicine Direct reversal of the suppressive function of cd4+ regulatory t cells via toll-like receptor 8 signaling
EP1924279A2 (en) * 2005-09-07 2008-05-28 The Secretary of State for Defence Adjuvanted vaccine
WO2011008305A1 (en) * 2009-07-15 2011-01-20 Enzon Pharmaceuticals, Inc. Rna antagonists targeting gli2 for the treatment of leukemia
WO2010093906A2 (en) * 2009-02-12 2010-08-19 Curna, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (en) 2009-06-29 2010-12-06 압타바이오 주식회사 Novel guanosine rich modified oligonucleotides and antiproliferative activity thereof
US20150045248A1 (en) * 2012-02-28 2015-02-12 National University Corporation Tokyo University Of Agriculture And Technology Method for identifying disease associated with abundance of tdp-43 in cell

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (en) * 1971-11-19 1975-02-07 Anvar
CH602920A5 (en) * 1973-02-23 1978-08-15 Wellcome Found
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042B1 (en) * 1976-06-04 1980-04-30 Merieux Inst
JPS6241214B2 (en) * 1978-03-10 1987-09-02 Mitsui Toatsu Chemicals
DE3011461C2 (en) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Koeln, De
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (en) * 1984-06-23 1986-02-06 Boehringer Ingelheim Int Synergistic mixtures of interferons and tumor necrosis factor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (en) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotic expression vectors with multimeric enhancer subelements, process for their production and use
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US6475795B1 (en) * 1991-07-03 2002-11-05 Meditech Research, Ltd. Use of hyaluronan in gene therapy
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
IE920561A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for thrombin and methods of use
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
IL107150D0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
CN1102855C (en) * 1993-01-29 2003-03-12 维特里制药有限公司 Immunotherapeutic composition
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1164869A (en) * 1994-08-30 1997-11-12 联邦科学和工业研究组织 Plant transcription regulators from circovirus
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (en) * 1995-02-14 1998-05-30 Bioniche Inc A process for preparing a hyaluronic acid solution
CN1154702A (en) 1995-05-19 1997-07-16 海布里登公司 Oligonucleotides with anti-cytomegalovirus activity
ZA9604446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
CA2236825A1 (en) 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
IT1277025B1 (en) * 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po oligonucleotide phosphodiester Class to attivita 'cytotoxic pharmaceutical compositions containing them and their use
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
EP1011729B1 (en) * 1996-05-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligonucleotides which specifically bind retroviral nucleocapsid proteins
DE69809561T2 (en) * 1997-08-05 2003-09-25 Bioniche Life Science Inc Composition and method for regulation of cell proliferation and cell death
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
DE60043759D1 (en) * 1999-12-13 2010-03-11 Bioniche Life Sciences Inc Therapeutically useful synthetic oligonucleotides
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
DK1432450T3 (en) * 2001-10-03 2006-05-15 Bioniche Life Sciences Inc Therapeutically useful triethyleneglycol cholesteryl-oliconucleotider
CN101160399A (en) * 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 Oligonucleotide compositions and their use for the modulation of immune responses

Also Published As

Publication number Publication date
MXPA02005842A (en) 2003-10-14
IL150196A (en) 2009-06-15
CA2393808A1 (en) 2001-06-21
IL150196D0 (en) 2002-12-01
AU785212B2 (en) 2006-11-09
PT1238070E (en) 2007-11-06
CN1433469A (en) 2003-07-30
ES2288883T3 (en) 2008-02-01
AT370231T (en) 2007-09-15
DE60036019D1 (en) 2007-09-27
AT455851T (en) 2010-02-15
DK1867718T3 (en) 2010-04-12
CN100445380C (en) 2008-12-24
HU0300627A2 (en) 2004-06-28
EP1238070B1 (en) 2007-08-15
EP1867718A3 (en) 2008-04-02
WO2001044465A3 (en) 2001-11-29
ES2340807T3 (en) 2010-06-09
US20070213291A1 (en) 2007-09-13
CZ20022372A3 (en) 2002-11-13
DK1238070T3 (en) 2007-12-03
CN101491536B (en) 2012-07-04
EP1867718A2 (en) 2007-12-19
HU0300627A3 (en) 2005-11-28
DE60036019T2 (en) 2008-05-29
JP4772245B2 (en) 2011-09-14
EP1238070A2 (en) 2002-09-11
WO2001044465A2 (en) 2001-06-21
NO20022820A (en) 2002-08-08
EP1867718B1 (en) 2010-01-20
JP2003517041A (en) 2003-05-20
US20010041681A1 (en) 2001-11-15
AU1847901A (en) 2001-06-25
CN101491536A (en) 2009-07-29
NO20022820D0 (en) 2002-06-13
US7157436B2 (en) 2007-01-02
NO330508B1 (en) 2011-05-09

Similar Documents

Publication Publication Date Title
DE60027737D1 (en) Düsenabdeckeinrichtung
DE60037462D1 (en) Facettenarthroplastiegeräte
DE60044918D1 (en) Embolifiltersystem
DE60039687D1 (en) Mpfängern
DE60038372D1 (en) Intraokularlinsenkombinationen
DE60031997D1 (en) Umkehrtransfektionsverfahren
DE60044373D1 (en) Durchflusszytometerprobenbehandlungsverfahren
DE60044885D1 (en) Strahlungsapplikator
DE60015735D1 (en) Axialflussmähdrescher
DE60016844D1 (en) Brachytherapiepatrone
DE60020240D1 (en) Meerwellenenergieumwandler
DE60005976D1 (en) Speicherkkarte
DE60044365D1 (en) Loid-deposit
AT262883T (en) Flüssigkeitstransferset
AT322870T (en) Photoablationssystem
AT434405T (en) Biosignalüberwachungssystem
AT299728T (en) Dosierungsbegrenzer
DE122007000064I2 (en) Erythropoietinkonjugate
AT258417T (en) Microcapsules - i
AT271400T (en) inhalateur
AT264863T (en) 28-epirapaloge
AT244898T (en) Tropfenzentrierungsverfahren
AT261288T (en) Zerflüssigungshandstück
AT287661T (en) Augenanalytfühler
AT289118T (en) Flachantenne

Legal Events

Date Code Title Description
8364 No opposition during term of opposition